Krop Julie 4
4 · Aquestive Therapeutics, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Aquestive (AQST) Director Julie Krop Receives Award — 50,500 Shares
What Happened Julie Krop, a director of Aquestive Therapeutics (AQST), received a grant of derivative awards covering 50,500 shares on June 10, 2026. The filing reports an acquisition price of $0.00 (total reported value $0) and classifies the grant as a derivative award. The award vests 100% on June 10, 2027, subject to her continued service through that date.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely).
- Award type: Derivative grant covering 50,500 shares; reported price $0.00; total reported value $0.
- Vesting: 100% of the underlying shares vest on June 10, 2027, contingent on continuous service (per footnote).
- Shares owned after transaction: Not specified in the filing.
- No 10b5-1 plan, tax withholding, or sale was reported in this filing.
Context This was a compensation-related award (derivative/option-style grant), not a market purchase or sale — it does not represent immediate proceeds or a disposition. The award will only convert into exercisable/vested shares if vesting conditions are met; retail investors typically view grants as routine executive/director compensation rather than a direct signal to buy or sell stock.
Insider Transaction Report
- Award
Stock Option (Right to Purchase)
[F1]2026-06-10+50,500→ 50,500 totalExercise: $3.99From: 2027-06-10Exp: 2036-06-10→ Common Stock (50,500 underlying)
Footnotes (1)
- [F1]The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date.